Medicine and HealthNature Communications
Neutralizing IFNγ Improves Safety without Compromising Efficacy of CAR-T Cell Therapy in B-cell Malignancies
S. Manni, F. D. Bufalo, et al.
Discover groundbreaking research by Simona Manni and colleagues that reveals how IFNγ neutralization with emapalumab can reduce the severe side effects of CAR-T cell therapy, while preserving its effectiveness against B-cell malignancies. This study highlights a promising combination therapy approach that could transform treatment protocols.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J. Zhang, Y. Hu, et al.
Medicine and Health
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
H. K. Tang, C. Tang, et al.
Medicine and Health
Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
C. Zheng, H. Lu, et al.
Medicine and Health
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
T. B. Dorff, M. S. Blanchard, et al.
